Maximizing the Clinical & Commercial Opportunity of the Adenosine-Pathway as a Second-Generation Immuno-Oncology Target
Harnessing Mono/Combo Adenosine Pathway Inhibition to Overcome Hypoxia & Immunosuppression in the Tumor Microenvironment
With 9 preclinical candidates actively being studied and 21 clinical trials taking place, the Adenosine landscape is bubbling with activity! No stone is left unturned as CD73, CD39, A1AR, A2AR, and Interior adenosine pathways are exploited. The field is poised to leap on the momentum from clinical success at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit.
Returning as the premier event devoted to improving the efficacy of drugs that target the adenosine pathway, overcoming obstacles related to resistance and immunosuppression, and accelerating the translation of therapeutics into the clinic.
Join experts in adenosine, immune checkpoint, tumor microenvironment, immune-oncology, and second-generation IO as they learn how combination medicines might improve the effectiveness and potency of treatment.
With more speakers, content, and networking opportunities than ever before, don't miss this opportunity to overcome these obstacles and exploit the adenosine pathway's therapeutic and commercial potential.
Unmissable Highlights:
Deep Diving into case studies of how mAB candidates are advancing and achieving ever more positive outcomes in the clinic and how their current learnings are shaping the future of adenosine therapeutics with AstraZeneca
Bolster your understanding of the core mechanisms behind Adenosine induction of hypoxia and angiogenesis mechanisms in cancer, and how targeting these improve patient outcomes with Harvard Medical
School
Solving the challenges in maximizing tumor killing, cell recruitment, and safety by selecting the right combination partner or bispecific components with Phanes Therapeutics and Elpiscience
Overcoming the immunosuppressive TME by understanding the underpinning immunosuppressive mechanisms caused by adenosine signaling and enzymology with Rutgers University and the University of Turku
Forecasting the future of the adenosine field and assess the potential outcomes of approval or major failure with ITeos Therapeutics and Trishula Therapeutics
2023 World-Class Speaker Faculty Including:
Achim Moesta
Executive Director, Vice President & Head of Immunology & Translational Sciences
Trishula Therapeutics, Inc.
Hear What Previous Attendees Have Said:
"Great opportunity to meet a number of key scientists involved in foundational work on adenosine pathway" - AstraZeneca
"Good conference that brought together leaders in the field to provide their unique perspectives" - Incyte Corporation
"Intensive discussions by the researchers/scientist in the field" - Brightpath Therapeutics